Skip to content
Screener

Rigel Pharmaceuticals RIGL Long-Term Debt

Long-Term Debt at other companies

Amgen logo
AmgenAMGN
$51.86B-3.5%
Nuvation Bio logo
Nuvation BioNUVB
$0-100%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$0-100%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$18.94M-36.9%
TG Therapeutics logo
TG TherapeuticsTGTX
$745.39M+204%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$1.13B—

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K—
Free cash flow-$22.0M—

Valuation

See full
Market cap$750.37M+29.7%
Enterprise value$794.27M+50.0%
P/E2.1×-3.9×
P/S2.5×+0.3×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%—

Returns & leverage

See full
Return on equity174.1%—
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebt.

The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:05 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001034842-26-000032
Remainder of 2026$22,500
202722,500
Principal amount (Tranches 1, 2, 3 and 4)$45,000

Item 1. Financial Statements

FAQ

What is Rigel Pharmaceuticals's long-term debt?
Rigel Pharmaceuticals (RIGL) reported long-term debt of $45M in Q1 2026.
What does long-term debt mean?
Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.

Ask your AI about Rigel Pharmaceuticals's long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude